Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer

Basit Öğe Kaydı
dc.contributor.authorKorkmaz, Elif Tuğçe
dc.contributor.authorKöksal, Deniz
dc.contributor.authorAksu, Funda
dc.contributor.authorDikmen, Z. Günnür
dc.contributor.authorİçen, Duygu
dc.contributor.authorMaden, Emin
dc.contributor.authorEmri, Salih
dc.date.accessioned2021-05-15T12:41:40Z
dc.date.available2021-05-15T12:41:40Z
dc.date.issued2018
dc.departmentTıp Fakültesi, Göğüs Hastalıkları Anabilim Dalıen_US
dc.descriptionKoksal, Deniz/0000-0001-8374-3691
dc.description.abstractBackground and aim: Early diagnosis and histological subtyping are important issues in the management of patients with lung cancer (LC). The aim of this study is to investigate the diagnostic value of a panel of serum tumor markers in newly diagnosed patients with LC. Methods: Venous blood samples were collected from 99 patients with LC (42 adenocarcinoma, 35 squamous, and 22 small cell carcinoma) and 30 patients with benign lung disease. Progastrin releasing peptide (ProGRP), squamous cell carcinoma antigen (SCCAg), cytokeratin 19-fragments (CYFRA 21.1), human epididymis protein 4 (HE4), Chromogranin A (CgA) and neuron specific enolase (NSE) levels were measured. The diagnostic value of the biomarkers was assessed with ROC curve analyses; the area under the curve (AUC) was calculated. Results: Serum CYFRA 21.1, ProGRP, SCCAg, NSE levels were significantly higher in LC patients. While ProGRP levels were higher (p = 0.009) in SCLC; CYFRA 21.1 and SCCAg levels were higher in NSCLC (p = 0.019 and p = 0.001, respectively). The sensitivity and specificity of tumor markers were 72%, 83% for CYFRA 21.1; 70%, 57% for HE4; 18%, 93% for ProGRP; 43%, 77% for SCCAg; 54%, 53% for CgA; 73%, 50% for NSE. CYFRA 21.1 (p < 0.001, r = 0.394), HE4 (p = 0.014, r = 0.279) and CgA (p = 0.023, r = 0.259) levels were positively correlated with tumor stage in NSCLC. CgA levels were significantly higher in extensive stage SCLC (p = 0.004). CYFRA 21.1 had the highest diagnostic value for LC (AUC = 0.865). When it is combined with HE4, diagnostic value increased (AUC = 0.899). ProGRP had the highest diagnostic value (AUC = 0.875, p < 0.001) for discriminating SCLC from NSCLC. Conclusion: A panel of three tumor markers CYFRA 21.1, HE4 and ProGRP may play a role for discriminating LC from benign lung disease and subtyping as SCLC.en_US
dc.description.sponsorshipHacettepe University Scientific Research UnitHacettepe University [014D12101003-818]en_US
dc.description.sponsorshipStudy was supported by Hacettepe University Scientific Research Unit (Project ID: 014D12101003-818).en_US
dc.identifier.doi10.1016/j.clinbiochem.2018.05.001
dc.identifier.endpage19en_US
dc.identifier.issn0009-9120
dc.identifier.issn1873-2933
dc.identifier.pmid29729229
dc.identifier.scopus2-s2.0-85046783420
dc.identifier.scopusqualityQ2
dc.identifier.startpage15en_US
dc.identifier.urihttps://doi.org/10.1016/j.clinbiochem.2018.05.001
dc.identifier.urihttps://hdl.handle.net/20.500.12939/837
dc.identifier.volume58en_US
dc.identifier.wosWOS:000438388500003
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorEmri, Salih
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofClinical Biochemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLung Canceren_US
dc.subjectDiagnosisen_US
dc.subjectTumor Markersen_US
dc.subjectBiomarkersen_US
dc.titleTriple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu